Company profile for Baudax Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients in acute care settings. Baudax Bio was spun-out from Recro Pharma, Inc (REPH) in 2019 when Recro Pharma, Inc. separated its Acute Care Division from its Contract Drug Manufacturing Organization that together were “Recro Pharma”. We are committed to bringing clinically meaningful therapeutic options to...
Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients in acute care settings. Baudax Bio was spun-out from Recro Pharma, Inc (REPH) in 2019 when Recro Pharma, Inc. separated its Acute Care Division from its Contract Drug Manufacturing Organization that together were “Recro Pharma”. We are committed to bringing clinically meaningful therapeutic options to patients, health care providers, and payers, such as our lead product candidate, injectable meloxicam. We believe we can create value for patients and shareholders through our robust pipeline of product candidates.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
490 Lapp Road Malvern, PA 19355
Telephone
Telephone
484-395-2440
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Baudax Bio Announces Corporate Update
Baudax Bio Announces Corporate Update

18 Oct 2023

// GLOBENEWSWIRE

https://www.globenewswire.com//news-release/2023/10/18/2762296/0/en/Baudax-Bio-Announces-Corporate-Update.html

GLOBENEWSWIRE
18 Oct 2023

https://www.globenewswire.com//news-release/2023/09/28/2751180/0/en/Baudax-Bio-Announces-Orphan-Drug-Designation-Granted-by-U-S-FDA-for-TI-168-for-the-Treatment-of-Hemophilia-A-with-Inhibitors.html

GLOBENEWSWIRE
28 Sep 2023

https://www.globenewswire.com//news-release/2023/09/07/2739292/0/en/Baudax-Bio-to-Participate-in-the-H-C-Wainwright-Global-Investment-Conference.html

GLOBENEWSWIRE
07 Sep 2023

https://www.globenewswire.com//news-release/2023/08/23/2730353/0/en/Baudax-Bio-Announces-Distribution-of-Series-C-Preferred-Stock-to-Holders-of-its-Common-Stock.html

GLOBENEWSWIRE
23 Aug 2023

https://www.globenewswire.com//news-release/2023/08/17/2727199/0/en/Baudax-Bio-Announces-1-9-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html

GLOBENEWSWIRE
17 Aug 2023

https://www.globenewswire.com//news-release/2023/08/16/2726283/0/en/Baudax-Bio-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
16 Aug 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty